153 related articles for article (PubMed ID: 19105707)
1. Extreme hypofractionation for prostate cancer.
Lee WR
Expert Rev Anticancer Ther; 2009 Jan; 9(1):61-5. PubMed ID: 19105707
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionation for prostate cancer: a critical review.
Miles EF; Lee WR
Semin Radiat Oncol; 2008 Jan; 18(1):41-7. PubMed ID: 18082587
[TBL] [Abstract][Full Text] [Related]
3. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
Xiong W; Li J; Ma CM
Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338
[TBL] [Abstract][Full Text] [Related]
4. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
[TBL] [Abstract][Full Text] [Related]
5. Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer.
Lennernäs B; Albertsson P; Edgren M; Nilsson S
Oncol Rep; 2007 Nov; 18(5):1299-303. PubMed ID: 17914588
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
[TBL] [Abstract][Full Text] [Related]
7. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
Leborgne F; Fowler J
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
[TBL] [Abstract][Full Text] [Related]
8. External beam irradiation for localized prostate cancer--the promise of hypofractionation.
Loblaw DA; Cheung P
Can J Urol; 2006 Feb; 13 Suppl 1():62-6. PubMed ID: 16526985
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
Coote JH; Wylie JP; Cowan RA; Logue JP; Swindell R; Livsey JE
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1121-7. PubMed ID: 19131179
[TBL] [Abstract][Full Text] [Related]
10. Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients.
Dasu A; Toma-Dasu I
Acta Oncol; 2012 Nov; 51(8):963-74. PubMed ID: 22966812
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio--possible reasons for concerns? An example of five dimensional radiotherapy.
Lennernäs B; Nilsson S; Levitt S
Acta Oncol; 2011 Jun; 50 Suppl 1():111-5. PubMed ID: 21604950
[TBL] [Abstract][Full Text] [Related]
12. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer.
Strigari L; Arcangeli G; Arcangeli S; Benassi M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1454-60. PubMed ID: 18990503
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated radiotherapy in prostate cancer.
Vavassis P; Nguyen DH; Bahary JP; Yassa M
Expert Rev Anticancer Ther; 2012 Jul; 12(7):965-72. PubMed ID: 22845411
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionation regimens for stereotactic radiotherapy for large brain tumors.
Yuan J; Wang JZ; Lo S; Grecula JC; Ammirati M; Montebello JF; Zhang H; Gupta N; Yuh WT; Mayr NA
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):390-7. PubMed ID: 18374501
[TBL] [Abstract][Full Text] [Related]
16. Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction.
Lee WR
Future Oncol; 2007 Dec; 3(6):649-54. PubMed ID: 18041917
[TBL] [Abstract][Full Text] [Related]
17. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system.
Aneja S; Pratiwadi RR; Yu JB
Oncology (Williston Park); 2012 Jun; 26(6):512-8. PubMed ID: 22870533
[TBL] [Abstract][Full Text] [Related]
19. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
20. Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.
Pemberton LS; Din OS; Fisher PM; Hatton MQ
Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):161-7. PubMed ID: 19111452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
